Muscle wasting conditions

DUCHENNE MUSCULAR DYSTROPHY : an area of high medical need

Duchenne muscular dystrophy (DMD) is a progressive genetic disorder causing muscle degeneration, primarily affecting men as it is inherited in an X-linked recessive pattern. It results from mutations in the DMD gene, leading to a lack of dystrophin. Symptoms begin early in childhood, including difficulty in walking, climbing stairs, and muscle weakness. While there is no approved drug to date, several therapeutic options aim to slow progression and improve quality of life. Corticosteroids, such as prednisone, can delay muscle decline. Additionally, physical therapy, assisted ventilation, and cardiac medications help manage symptoms, enhancing mobility and heart function in patients with DMD.

of people affected 
worldwide

> 0 MM

Global Health costs
for DMLD

> 0 bn

pharmacological  
treatment to date

0 0

Models

We have extensively characterized different mdx mouse models that recapitulates most of the human DMD features and constitute excellent models to test your compounds’ effects on this pathology.

B10.MDX mice
D2.MDX mice

Methods

We master gold-standard methods to provide you with high-added value data about your health products efficacy and mechanisms of action on key hallmarks of DMD such as food and water intakes, fecal pellet output, circulating plasma biomarkers. In addition, we offer complementary techniques that allow performing histological and genomic analyses on key tissues and organs.